Search

Displaying results 1311 - 1320 of 8696 in total
  1. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

  2. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs [T28]. … Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.

  3. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

  4. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    allowing for administration in a one-hour infusion twice-a-year following the starting dose. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  5. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  6. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. … [A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs.

    Synonyms: (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanolMixtures: BISOPROLOL DURA P 5/12.5MG, BISOPROLOL DURA P 5/12.5MG
  7. Drug

    Butabarbital

    go.drugbank.com/drugs/DB00237
    ApprovedIllicitWithdrawn

    [A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. … [A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.

  8. Indication

    Early Estrogen Receptor Positive Breast Cancer

    go.drugbank.com/conditions/DBCOND0173171
    Drugs: Goserelin
    Synonyms: Early Estrogen Receptor Positive Breast Cancer
  9. Indication

    Metastatic Estrogen Receptor Positive Breast Cancer

    go.drugbank.com/conditions/DBCOND0129603
    Drugs: Tamoxifen
    Synonyms: Metastatic Estrogen Receptor Positive Breast Cancer
  10. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors